-
-
公开(公告)号:US20220017607A1
公开(公告)日:2022-01-20
申请号:US17182095
申请日:2021-02-22
发明人: Heinz HILLEN , Stefan BARGHORN , Boris LABKOVSKY , Ulrich EBERT , Andreas STRIEBINGER , Patrick KELLER
IPC分类号: C07K16/18 , A61K39/395 , G01N33/577 , G01N33/68
摘要: The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment, and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.
-
公开(公告)号:US20220008413A1
公开(公告)日:2022-01-13
申请号:US17193795
申请日:2021-03-05
IPC分类号: A61K31/496
摘要: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
-
公开(公告)号:US20220008290A1
公开(公告)日:2022-01-13
申请号:US17319917
申请日:2021-05-13
申请人: AbbVie Inc.
摘要: A child-resistant medication container assembly that includes a blister card including a plurality of compartments each configured to support a dosage of medication, and a puck including a body portion, a recess that defines a partition wall in the body portion, and a plurality of openings defined in the partition wall. Each opening corresponds to one of the plurality of compartments in the blister card. The assembly further includes a carton including a first wall opposite a second wall. An access opening is defined in the first wall and a plurality of perforations are defined in the second wall. The access opening is sized to provide access to the plurality of compartments, and each perforation corresponds to one of the plurality of compartments in the blister card.
-
公开(公告)号:US20210312797A9
公开(公告)日:2021-10-07
申请号:US16828351
申请日:2020-03-24
申请人: AbbVie Inc.
发明人: Mark Anderson , Jieyi Wang , Archana Thakur , Debra Chao , Chung-Ming Hsieh , Qian Zhang , Edward B. Reilly , Enrico L. Digiammarino , Kenton L. Longenecker , Russell A. Judge , David A. Egan , Charles W. Hutchins
摘要: The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).
-
公开(公告)号:US20210275528A1
公开(公告)日:2021-09-09
申请号:US17325900
申请日:2021-05-20
申请人: AbbVie Inc.
IPC分类号: A61K31/513 , A61K45/06 , A61K31/565 , A61K31/57 , A61P15/00
摘要: The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.
-
公开(公告)号:US11045480B2
公开(公告)日:2021-06-29
申请号:US16219450
申请日:2018-12-13
IPC分类号: C07K16/28 , C07K16/30 , C07K16/46 , A61K39/395 , A61K31/5517 , A61K38/07 , A61K47/68 , A61K39/00
摘要: The present disclosure provides antibodies, antibody binding fragments, and antibody drug conjugates that bind human LRRC15, their methods of making, and their uses to treat patients having cancer.
-
公开(公告)号:US20210155681A1
公开(公告)日:2021-05-27
申请号:US17034454
申请日:2020-09-28
IPC分类号: C07K16/18 , G01N33/566 , C07K16/28
摘要: Provided herein are methods of using the antibodies that bind to RGMc to treat and diagnose iron-related disorders.
-
公开(公告)号:US10954202B2
公开(公告)日:2021-03-23
申请号:US17025644
申请日:2020-09-18
发明人: Zhaoming Xiong , Jennifer M. Frost , Philip R. Kym , Xueqing Wang , Shuang Chen , Dennie Welch
IPC分类号: C07D285/10
摘要: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
-
公开(公告)号:US20210070756A1
公开(公告)日:2021-03-11
申请号:US17099133
申请日:2020-11-16
申请人: AbbVie Inc.
发明人: Steven D. Fidanze , Dachun Liu , Robert A. Mantei , Keith F. McDaniel , John Pratt , George S. Sheppard , Le Wang , Andrew Bogdan , James H. Holms , Justin D. Dietrich , Jasmina Marjanovic , Lisa A. Hasvold , Yujia Dai
IPC分类号: C07D471/22 , A61P15/16 , A61P31/18 , A61P13/12 , A61P35/00 , C07D471/16
摘要: The present invention provides for compounds of formula (I) wherein R1, R2, R6, Y1, Y2, Y3, A1, A2, A3, and A4 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising one or more compounds of formula (I).
-
-
-
-
-
-
-
-
-